Neurocrine Biosciences (NASDAQ:NBIX) Insider Ingrid Delaet Sells 2,737 Shares of Stock

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) insider Ingrid Delaet sold 2,737 shares of the stock in a transaction on Wednesday, July 8th. The stock was sold at an average price of $178.54, for a total value of $488,663.98. Following the completion of the transaction, the insider owned 16,225 shares of the company’s stock, valued at $2,896,811.50. The trade was a 14.43% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Ingrid Delaet also recently made the following trade(s):

• On Tuesday, July 7th, Ingrid Delaet sold 3,401 shares of Neurocrine Biosciences stock. The stock was sold at an average price of $178.57, for a total transaction of $607,316.57.
• On Thursday, July 9th, Ingrid Delaet sold 8,433 shares of Neurocrine Biosciences stock. The stock was sold at an average price of $178.72, for a total transaction of $1,507,145.76.
• On Friday, May 29th, Ingrid Delaet sold 2,261 shares of Neurocrine Biosciences stock. The shares were sold at an average price of $156.71, for a total transaction of $354,321.31.

Neurocrine Biosciences Stock Up 1.3%

Shares of NASDAQ NBIX opened at $180.55 on Friday. Neurocrine Biosciences, Inc. has a 52 week low of $122.14 and a 52 week high of $181.00. The firm has a 50-day moving average price of $159.92 and a 200 day moving average price of $142.66. The stock has a market capitalization of $18.15 billion, a price-to-earnings ratio of 27.82, a price-to-earnings-growth ratio of 0.71 and a beta of 0.39.

Analyst Ratings Changes

Several brokerages have recently commented on NBIX. Truist Financial boosted their price target on Neurocrine Biosciences from $140.00 to $155.00 and gave the stock a “buy” rating in a research note on Thursday, May 7th. HC Wainwright lifted their price objective on Neurocrine Biosciences from $192.00 to $215.00 and gave the stock a “buy” rating in a report on Tuesday, April 7th. Wall Street Zen upgraded Neurocrine Biosciences from a “buy” rating to a “strong-buy” rating in a research report on Saturday, April 25th. The Goldman Sachs Group assumed coverage on Neurocrine Biosciences in a report on Tuesday, June 2nd. They issued a “buy” rating and a $213.00 target price on the stock. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $185.00 price target on shares of Neurocrine Biosciences in a research note on Monday, April 6th. Two research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and three have issued a Hold rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $188.10.

Institutional Trading of Neurocrine Biosciences

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Nilsine Partners LLC acquired a new position in Neurocrine Biosciences in the 4th quarter valued at $1,197,000. Ruffer LLP purchased a new position in shares of Neurocrine Biosciences in the 4th quarter worth about $2,479,000. Korea Investment CORP lifted its position in Neurocrine Biosciences by 94.3% during the third quarter. Korea Investment CORP now owns 71,689 shares of the company’s stock valued at $10,064,000 after buying an additional 34,800 shares in the last quarter. Nordea Investment Management AB lifted its holdings in shares of Neurocrine Biosciences by 81.3% during the 4th quarter. Nordea Investment Management AB now owns 27,202 shares of the company’s stock valued at $3,834,000 after acquiring an additional 12,195 shares in the last quarter. Finally, CIBC Private Wealth Group LLC boosted its position in shares of Neurocrine Biosciences by 17,250.0% in the third quarter. CIBC Private Wealth Group LLC now owns 7,981 shares of the company’s stock worth $1,120,000 after buying an additional 7,935 shares during the period. Hedge funds and other institutional investors own 92.59% of the company’s stock.

Neurocrine Biosciences News Roundup

Here are the key news stories impacting Neurocrine Biosciences this week:

• Positive Sentiment: NBIX was upgraded to Zacks Rank #1 (Strong Buy), signaling improved earnings optimism and potentially supporting further upside. Article Title
• Positive Sentiment: News that Neurocrine has started a Phase 2 CAH study in children under 4 may be encouraging for the pipeline, and another article suggested the stock could be undervalued after the new study. Article Title Article Title
• Neutral Sentiment: Neurocrine announced it will host its second-quarter 2026 earnings conference call and webcast on July 30; this is important upcoming catalyst news, but it does not change fundamentals by itself. Article Title
• Neutral Sentiment: A separate note said NBIX looks fair on earnings but pricey versus biotechs, which is more of a valuation check than a clear stock-moving event. Article Title
• Negative Sentiment: Insider Ingrid Delaet sold shares in three transactions over July 7-9. The sales were made under a pre-arranged 10b5-1 plan, which limits how bearish the signal is, but insider selling can still temper enthusiasm. Article Title

Neurocrine Biosciences Company Profile

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.